Re-LuPSMA: Interim Safety Analysis of the Prospective Phase II Trial of 177Lu-PSMA-617 Retreatment in #mCRPC. Presented by Johanna Enke, MD, #ESMO26 written coverage by @zklaassen_

UroToday.com· @urotoday · X·2026-10-24 00:30· 2 天前评分45

正文 · 原文

Re-LuPSMA: Interim Safety Analysis of the Prospective Phase II Trial of 177Lu-PSMA-617 Retreatment in #mCRPC. Presented by Johanna Enke, MD, #ESMO26 written coverage by @zklaassen_md > https://bit.ly/4i3xD2l #ProstateCancer @myESMO

248 浏览 · 2 赞 · 1 转发 · 0 回复

来源：UroToday.com · x.com